2025360-91-0
2025360-91-0
Chemical Structure
(R)-Azasetron besylate
Synonym(s): SENS-401
- CAS. Nr.: 2025360-91-0
- Formula:C23H26ClN3O6S
- Molecular Weight:507.99
InChIKey: GFVBDLIBPSGFDL-ZOWNYOTGSA-N
SMILES: O=S(O)(C1=CC=CC=C1)=O.O=C(C2=C(OCC(N3C)=O)C3=CC(Cl)=C2)N[C@H]4CN5CCC4CC5
Biological Activity: (R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (HY-17394)-induced hearing loss and cochlear damage[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-Azasetron besylate | 99.65% | (R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (HY-17394)-induced hearing loss and cochlear damage. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Petremann M, et al. SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96 hours. Otol Neurotol. 2019 Feb;40(2):254-263. [Content Brief]
- [2]. Petremann M, et al. Oral Administration of Clinical Stage Drug Candidate SENS-401 Effectively Reduces Cisplatin-induced Hearing Loss in Rats. Otol Neurotol. 2017 Oct;38(9):1355-1361. [Content Brief]
